Results 21 to 30 of about 13,220 (219)

Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016)

Antimicrobial Resistance and Infection Control, 2020
Background This study reports the global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam using data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program between 2012 and 2016.
Hui Zhang, Yingchun Xu, Peiyao Jia, Ying Zhu, Ge Zhang, Jingjia Zhang, Simeng Duan, Wei Kang, Tong Wang, Ran Jing, Jingwei Cheng, Yali Liu, Qiwen Yang   +12 more
doaj   +1 more source

In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan

Microorganisms, 2020
Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime–avibactam and aztreonam–avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must ...
Tsung-Ying Yang, Ya-Ju Hsieh, Li-Ting Kao, Guan-Hong Liu, Shao-Hsuan Lian, Liang-Chun Wang, I-Ling Lin, Yu-Tzu Lin, Sheng-Fan Wang, Sung-Pin Tseng, Po-Liang Lu   +10 more
doaj   +1 more source

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia [PDF]

, 2020
BACKGROUND: Cefiderocol is a novel siderophore cephalosporin, developed for activity against MDR Gram-negative bacilli (MDR-GNB). OBJECTIVES: To assess the in vitro antibacterial activity of cefiderocol against a collection of MDR-GNB clinical ...
Conejo, Mª del Carmen, Delgado Valverde, María Mercedes, Fernández Cuenca, Felipe Manuel, Pascual Hernández, Álvaro, Serrano, Lara   +4 more
core   +1 more source

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam

WIREs Mechanisms of Disease, 2022
AbstractCeftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β‐lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the National Regulatory Administration in China. CAZ/AVI is used mainly to treat complicated urinary tract infections and complicated intra‐abdominal
Luying Xiong, Xueting Wang, Yuan Wang, Wei Yu, Yanzi Zhou, Xiaohui Chi, Tingting Xiao, Yonghong Xiao   +7 more
openaire   +2 more sources

Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales

Antibiotics, 2020
Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram−negative bacteria (GNB) other than carbapenem-resistant Enterobacterales (CRE) is very limited.
Antonio Vena, Daniele Roberto Giacobbe, Nadia Castaldo, Annamaria Cattelan, Cristina Mussini, Roberto Luzzati, Francesco Giuseppe De Rosa, Filippo Del Puente, Claudio Maria Mastroianni, Antonio Cascio, Sergio Carbonara, Alessandro Capone, Silvia Boni, Chiara Sepulcri, Marianna Meschiari, Francesca Raumer, Alessandra Oliva, Silvia Corcione, Matteo Bassetti, for the Ceftabuse Study Group   +19 more
doaj   +1 more source

In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing Klebsiella pneumoniae Clinical Isolates

Antibiotics, 2023
The novel β-lactam/β-lactamase inhibitor combinations (βL-βLICs) are one of the last-line resources available against multidrug-resistant (MDR) Gram-negative bacteria.
Marta Palombo, Benedetta Secci, Federica Bovo, Milo Gatti, Simone Ambretti, Paolo Gaibani   +5 more
doaj   +1 more source

Multi-drug resistant Gram-negative bacteria: antibiotic-resistance and new treatment strategies [PDF]

, 2017
In this editorial, we treat the multi-drug-resistance of microorganisms such as Klebsiella pneumonia (Kp) and Acinetobacter baumanii and the issues concerning the management of these infections.
Angelis, Massimiliano De, Mascellino, Maria Teresa, Oliva, Alessandra   +2 more
core   +1 more source

The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study

Infectious Diseases and Therapy, 2023
Introduction Ceftazidime–avibactam has proven activity against multidrug-resistant (MDR) bacteria in clinical trials and real-world studies. This study was conducted to describe the patterns of use of ceftazidime–avibactam (including indications and ...
Alex Soriano, Philippe Montravers, Matteo Bassetti, Galina Klyasova, George Daikos, Paurus Irani, Gregory Stone, Richard Chambers, Pascale Peeters, Mitesh Shah, Claire Hulin, Natalia Albuquerque, Efim Basin, Benjamin Gaborit, Irene Kourbeti, Francesco Menichetti, María Teresa Perez-Rodriguez, Mathias W. Pletz, Marisa Sanchez, Ivan Trompa, Anita Verma, Maria Lavinea N. de Figueiredo, Claudie Charbonneau   +22 more
doaj   +1 more source

IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND COLISTIN AGAINST CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA CLINICAL ISOLATES

İstanbul Tıp Fakültesi Dergisi, 2022
Objective: Infections caused by multi drug-resistant Gram-negative bacilli are increasingly reported worldwide. Ceftazidime-avibactam is a novel antibiotic combination that presents good activity against carbapenem-resistant Enterobacterales members and ...
Tuğrul Hoşbul, Canset Nur Aydoğan, Sinem Kaya, Orhan Bedir, Hande Özcan, Ramazan Gümral   +5 more
doaj   +1 more source

The 2018 Garrod Lecture: Preparing for the Black Swans of Resistance [PDF]

, 2018
The need for governments to encourage antibiotic development is widely agreed, with ‘Market Entry Rewards’ being suggested. Unless these are to be spread widely – which is unlikely given the $1 billion sums proposed– we should be wary, for this approach ...
Livermore, David
core   +1 more source